Knee arthroplasty is a procedure performed by DePuy Synthes, a Florida-based orthopaedics company under Johnson & Johnson, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Velys robotic-assisted system, expanding its clinical application to include unicompartmental (UKA) procedures. This clearance follows a previous approval for the device’s use in total knee arthroplasty (TKA). The Velys system, designed for both medial and lateral procedures, aims to enable surgeons to perform surgeries without the need for a preoperative CT scan.
Unicompartmental knee arthroplasty, also known as partial knee replacement, is gaining popularity due to its potential to shorten patient recovery times and preserve bone. Research published in the Journal of Orthopaedics and Traumatology highlights its benefits in bone preservation. According to GlobalData, the total number of partial knee reconstruction procedures in North America is expected to increase from 36,994 to 78,457 annually by 2030, with the market projected to reach $837 million by the end of the same year.
Aldo Denti, the company group chairman at DePuy Synthes, expressed excitement about expanding their Velys Enabling Technology portfolio to include robotic-assisted UKA, addressing unmet needs in the partial knee replacement segment such as accuracy and simplicity. The company aims to leverage data and analytics to provide real-time insights for surgeons, empowering them to make patient-specific operative decisions and improve outcomes.
DePuy Synthes Expands Velys Robotic System for Knee Arthroplasty, Highlighting Innovations in Orthopedics
DePuy Synthes’ recent clearance for its Velys robotic-assisted system marks another significant step in advancing knee care. This development, expanding the clinical application to include unicompartmental knee arthroplasty (UKA) procedures, comes on the heels of the company’s clearance for the TriLeap lower extremity anatomic plating system. The TriLeap system, utilized in stabilizing bones during bunionectomy procedures, showcases the company’s commitment to providing comprehensive solutions across various orthopedic procedures.
The orthopedic landscape is witnessing a wave of innovations aimed at improving knee replacement surgeries. Exactech, a US-based company, has introduced its ExactechGPS software system, designed to enhance total knee replacement surgeries. This technology underscores the industry’s focus on leveraging advanced software solutions to optimize surgical outcomes and patient experiences.
Brixton Biosciences and DePuy Synthes Lead Advances in Pain Management and Surgery
In addition to technological advancements, there is a growing emphasis on addressing pain management in knee-related conditions. Brixton Biosciences’ recent funding success, securing $33 million, highlights the significance of developing innovative solutions for osteoarthritis treatment. Their Neural Ice platform offers promising prospects for managing pain associated with osteoarthritis, signaling a holistic approach to knee care that encompasses both surgical innovations and post-operative management strategies.
Overall, DePuy Synthes’ expansion into robotic-assisted UKA, alongside other advancements in knee replacement surgery and pain management, reflects the evolving landscape of orthopedic care. These developments underscore the industry’s dedication to enhancing patient outcomes, improving surgical techniques, and advancing treatment options for knee-related conditions.
Resource: Johnson & Johnson, June 07, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
